Arrest of the company owner after children's deaths from syrup: investigation details.

Arrest of the owner of a pharmaceutical company due to children's deaths from syrup

According to inkorr.com: The police of Madhya Pradesh detained the owner of Sresan Pharma, which produced the cough syrup Coldrif. This syrup led to the deaths of at least 20 children. An inspection found that the syrup contained toxic diethylene glycol in dangerous quantities.

During the inspection at the Sresan Pharma facility, it was discovered that the syrup samples contained the toxic component diethylene glycol, which is used in the production of resins, paints, varnishes, inks, and adhesives. It was established that the company added 46-48% of the toxic substance instead of the permissible limit of 0.1%. Unregistered containers of diethylene glycol were found in the factory premises.

After the arrest, the owner of Sresan Pharma was charged with gross violations of production standards and non-compliance with raw material inspection requirements. The activity of the pharmaceutical company in Tamil Nadu was halted, and the company was stripped of its license. The sale of Coldrif syrup is banned in nine Indian states.

Investigation of Coldrif syrup due to toxic diethylene glycol

Earlier reports indicated that more than 10 children in India died after consuming the cough syrup, which contained a high concentration of toxic diethylene glycol. The Food and Drug Administration recommended revoking the manufacturer's license.

As a result of the tragedy involving children, the pharmaceutical company in India was stripped of its license, and the sale of Coldrif syrup was banned in nine states. The company owner has been charged with multiple violations of production standards.

Overall, the incident with Coldrif syrup underscores the critical importance of adhering to safety standards in the pharmaceutical industry. The swift reaction of authorities to cases of children's deaths indicates the need for strict quality control of medical products, as children's lives must always remain a priority. It is hoped that the consequences of this tragedy will lead to strengthened measures to ensure the safety of pharmaceuticals.